Predicting MEK inhibitor response in lung cancer: A proper signature is required Journal Article

  


Authors: Xue, Y.; Lito, P.
Article Title: Predicting MEK inhibitor response in lung cancer: A proper signature is required
Abstract: The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. © 2016 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 23
Issue: 6
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2017-03-15
Start Page: 1365
End Page: 1367
Language: English
DOI: 10.1158/1078-0432.ccr-16-2576
PROVIDER: scopus
PUBMED: 27923842
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016155057&doi=10.1158%2f1078-0432.CCR-16-2576&partnerID=40&md5=e572192769f8a85591e19ba0ac8cc19e
Notes: Article -- Export Date: 2 May 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Piro Lito
    58 Lito
  2. Yaohua Xue
    13 Xue
Related MSK Work